pharmaphorum
DECEMBER 8, 2016
With rising healthcare costs, more informed and engaged patients, and advancing technology, health wearables have seen a significant uptake in recent years. However, the full potential of health wearables has yet to be recognised and there are still challenges to be resolved. What needs to be done on the regulatory, technical and healthcare side to take health wearables to the next level?
The Digital Apothecary
NOVEMBER 19, 2016
I Just got my new iPhone 7. And I realize now that there are several devices I can no longer use. While many individuals were complaining about the removal of the 3.5 mm earphone jack and their now irrelevantearphones, I lamented the loss of many digital health tools in this generation of phone design. Then I realized that we had been down this road before, when the iPhone 5 had moved on from the 30-pin dock to the Lightning connector now ubiquitous across most recent generation iOS products.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Med Ed 101
DECEMBER 28, 2016
Tumeric and Apixaban – Guest Post by Amanuel Tseggai A 72 year old man was newly diagnosed with atrial fibrillation and started on therapeutic dose of Enoxaparin after he was admitted to a hospital. Four days into his treatment with Enoxaparin his primary care provider decided to switch him to Apixaban- one of the newer oral […]. The post Tumeric and Apixaban appeared first on Med Ed 101.
pharmaphorum
NOVEMBER 30, 2016
Join us and PHOENIX group as we delve into the concept of current launch excellence and the role of patient insights in overcoming the multiple challenges the industry currently faces. Key topics to be discussed include: – The challenges of launching a product in Europe – How pharma can improve its understanding of the process through the use of business intelligence – How insights from new data can be applied to the process of launch excellence – The role of real-world data in launch strategy –
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
pharmaphorum
NOVEMBER 22, 2016
Working with QuintilesIMS, we present a digital debate which will offer modellling-based insights into the future of hepatitis C treatment.
pharmaphorum
NOVEMBER 16, 2016
Over the past 20 years, behavioural economics has identified factors that influence and determine how people behave, including alternative decision-making pathways and many cognitive biases and heuristics. Taking account of these helps to build a clear view of how healthcare customers think and behave in relation to your product in the real world. This short masterclass explores ‘quantitative demand assessment research’ – what it is and how insights from behavioural economics can improve the app
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
pharmaphorum
SEPTEMBER 8, 2016
Diabetes is one of the most prevalent and most costly conditions worldwide – with a prevalence equating to 8.5% of the global population. Due to the complex nature of diabetes, with numerous co-morbidities and its asymptomatic nature, accurately modelling and therefore discerning which interventions are most effective, in terms of cost and patient impact is an equally complicated process.
pharmaphorum
AUGUST 2, 2016
Join us for a one-hour live debate on Cancer Treatment Access: Right Strategy, Right Approach, Right Outcomes. To ensure funding and patient access to innovative cancer therapies, industry now have to navigate a new English cancer-treatment funding ecosystem, engaging with NICE and NHS England to realise a yes, no or conditional arrangement. How can oncology treatments achieve a positive NICE appraisal in the new world and what will the mechanics of RWE be in the event of conditional funding via
pharmaphorum
JULY 12, 2016
Sanofi Pasteur MSD is transforming its commercial organisation and remodeling its approach to customer engagement. Hear from Sanofi Pasteur MSD’s Alexandre Gultzgoff, Deputy Director, IT, and Antoine Blanc, Commercial Excellence Director, as they share first hand insights on how they are transforming their European commercial operations and improving customer engagement.
The Digital Apothecary
JULY 10, 2016
The Premise It comes as no surprise that with all the hype surrounding the use of technology to transform healthcare, that companies (startups & Pharma) are looking to transform traditional medication use. As a pharmacist, this is perhaps the biggest interest I have in the Digital Health sphere, as I feel it may have the largest impact on my profession, and role as an educator.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
pharmaphorum
JUNE 28, 2016
In today’s competitive, highly regulated environment, product success is dependent upon data and fact-based decision making. More and more, Medical Affairs teams play a pivotal role in education pre- and post-launch, yet the explosion of big data in healthcare is changing how we make value-based decisions that are critical to success. This webinar will explore the challenges Medical Affairs teams have finding a repeatable, objective and compliant solution to identify and manage their strategic p
The Digital Apothecary
JUNE 28, 2016
The Issue: For many presentations I give throughout the year in different programs of my University, my slide deck inevitably ends up being the core study material for my students. While flipped classroom models and use of adjuntive material (e.g. videos/Youtube) have cut down on the amount of slides and time spent in class on cases and material, the slide deck still reigns supreme.
pharmaphorum
JUNE 27, 2016
The ASCO Annual Meeting, the largest global oncology meeting and increasingly the centre of a kaleidoscope of social media coverage each year. As a snapshot, 2014 saw 40,000 tweets and 140m+ impressions over the conference days, 2015 grew to 60,000 tweets and 250m+ impressions and the 2016 buzz is already louder and more plentiful than last year. This webinar will examine the conversation around ASCO 2016, its relationship with ASCO, value to and involvement from stakeholder groups and how it wi
pharmaphorum
APRIL 27, 2016
There are clear benefits for both Life Sciences companies and their customers in significantly improving the way they engage. Be it in terms of reputation, efficiency, profitability, or even relationship quality and longevity, engagement has and will always be the key to successful business practice. Recent exclusive research conducted in conjunction with Zephyr Health revealed that both frontline sales forces and sales management professionals want to improve engagement strategies with new tech
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
pharmaphorum
APRIL 26, 2016
Meeting the needs of both patients, and healthcare professionals, in today's fast changing communications landscape can be challenging, particularly against the backdrop of compliance. Putting creativity at the heart of the process can be the most effective way of tackling these challenges. Although the return on investment of creativity is not always easy to measure, the value it can bring to pharma and healthcare is increasingly evident.
pharmaphorum
FEBRUARY 23, 2016
According to the European Commission and NIHR Clinical Research Network, between 2007 and 2011, delays for launching clinical trials rose by 90%. And with approximately one third of the clinical trial timeline spent in patient recruitment, delays in launching clinical trials will increase costs and drain resources. As our industry moves to become fully and demonstrably patient centric, there is much focus on the materials and media which are often the key liaison with the patient populous.
pharmaphorum
FEBRUARY 11, 2016
The first in a trilogy of webinars focussed on the topic; Unlocking the value; the economic equation and part of the IMS Health Practical Insights series. While it remains the gold standard, the feasibility of large scale randomised clinical trials within a pipeline that is ever more focused on niche and personalised medicines is decreasing – particularly in the fields of rare diseases and oncology.
The Digital Apothecary
FEBRUARY 4, 2016
Recently I went up for advancement from provisional status. Due in part of my love of trying to make things graphically appealing and as a format to get a story across, I attempted to make two infographics detailing my scholarly activities. The first one was a graphic outlining what classes I have taught or been involved with during my time at the university.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
pharmaphorum
JANUARY 27, 2016
The current market research climate in the pharmaceutical industry is one of “doing more with less”. At the same time the number of healthcare professionals engaging with market research is on the decline. So how do marketing teams cope with these two challenges and continue to produce good business intelligence for big brand decisions? Cello Health Insight’s quantitative team, IQ, argues that this is an ideal environment in which to start making greater use of advanced analytics techniques to m
Med Ed 101
DECEMBER 25, 2016
Drug interactions can make medication management challenging. Here’s a classic case demonstrating the rifampin and phenytoin interaction. A 47 year old patient with diabetes and seizure disorder is diagnosed with new onset osteomyelitis. The patient’s seizures were well controlled on phenytoin as they had not had one in well over a year.
Med Ed 101
DECEMBER 21, 2016
We all know the negatives of warfarin, but lets take a look at the advantages of warfarin. NOACs are gaining in popularity, no doubt about that. No matter which anticoagulant we are using, we must recognize that there are always positives and negatives. It is incredibly important to recognize those positives and negatives to best […]. The post What Advantages Does Warfarin Have Over NOACS?
Med Ed 101
DECEMBER 14, 2016
Selecting a medication for diabetic neuropathy can be a bit challenging. You really need to weigh the adverse effect profile when choosing an agent. The case: A 55 year old male has a past medical history of diabetes. He has been experiencing tingling in his feet which hasn’t been too troublesome until lately. This has […]. The post Selecting A Medication For Diabetic Neuropathy appeared first on Med Ed 101.
Med Ed 101
DECEMBER 11, 2016
GF is a 77 year old male with a past medical history of BPH, COPD, hypertension, constipation, Barrett’s esophagus, and anemia. Of late, he has had recurrent pneumonia episodes requiring frequent antibiotic use. He has had 3 courses of antibiotics within the last four months to treat pneumonia. His current medication list includes; Aspirin 81 […].
Med Ed 101
DECEMBER 7, 2016
Albumin is a protein found in the bloodstream of the body, and it can have a significant impact on medications. One of those classic medications that albumin can impact is phenytoin. Albumin and phenytoin stick together. How does this matter clinically? When albumin levels are higher (or normal) there is more albumin available to “stick” […].
Med Ed 101
DECEMBER 4, 2016
You will find a comparison of warfarin and NOACS below. Both medication classes are frequently used in practice and a familiarity with these agents is necessary for any practicing pharmacist. A huge thank you to Aisha Shokoya for putting the majority of this table together. If you notice something that should be added or changed, please […].
Med Ed 101
NOVEMBER 30, 2016
As a practicing pharmacist, I continue to hear rumblings and news trickle in about the 2017 pharmacy job outlook. Fellow pharmacist blogger Jason Poquette put together a nice article early in 2016 about what the pharmacy job outlook looks like. It wasn’t very good unfortunately. As I focus ahead to the 2017 pharmacy job outlook, Pharmacist […].
Med Ed 101
NOVEMBER 27, 2016
I have encountered the use of Fleets enema in the elderly a few times. One of the most important things to look for when using this medication is kidney function. The FDA did issue warnings for the oral preparation of this sodium phosphate to treat constipation, but Fleets enema is still available over the counter. So […]. The post Using Fleets Enema in the Elderly appeared first on Med Ed 101.
Med Ed 101
NOVEMBER 23, 2016
It is time to point the finger outward at people who deserve my thanks. You don’t know how much it means to me that so many of you come read my blog posts day after day. The even better part for me is that many of you have taken time out of your day to […]. The post Time to Give Thanks and Can Someone Teach Me How To Do Laundry? appeared first on Med Ed 101.
Med Ed 101
NOVEMBER 20, 2016
MAOI’s (mono-amine oxidase inhibitors) can be used for depression. With that stated, they have a significant number of clinical pearls that limit there use. MAOI’s and drug interactions are two terms that you should lump together. Very rarely do I see patients on MAOI’s for depression. Often you’ll find that the patients that are taking […].
Med Ed 101
NOVEMBER 16, 2016
A 59 year old female is on the following medications: Alprazolam 1 mg four times daily as needed Norvasc 10 mg daily Simvastatin 40 mg at bedtime Cyclobenzaprine 10 mg hs prn Tylenol PM as needed Lasix 20 mg daily Glucagon kit as needed Glipizide 5 mg daily Lantus 18 units daily Humalog 8 units […]. The post The Dreaded Glucagon for Hypoglycemia Order appeared first on Med Ed 101.
Med Ed 101
NOVEMBER 9, 2016
Urine drug screens are often confusing if you don’t interpret them on a regular basis. I think a big reason for confusion is a lack of education on what these tools can do and what they look at. I would definitely classify myself as needing to learn more about drug screen interpretation. The case: A […]. The post Patient Reports They Are On Morphine – So Why is a Urine Drug Screen Negative?
Med Ed 101
NOVEMBER 6, 2016
A 67 year old male has a past medical history of hypertension, atrial fibrillation, CHF, and osteoarthritis. He has had numerous issues with his cardiac status and it has led him to frequent physician visits, including involvement of a cardiologist. This gentleman has been on digoxin 250 mcg daily with digoxin levels around the 0.8 […]. The post Amiodarone Digoxin Interaction appeared first on Med Ed 101.
pharmaphorum
NOVEMBER 2, 2016
Senior level expert panel debate on the likely impacts of a hard v soft Brexit for life sciences companies in Britain.
Expert insights. Personalized for you.
52 
Let's personalize your content